Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Venetoclax in R/R B-cell NHL
NCT03886649Phase 1Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib and venetoclax in B-cell non-Hodgkin lymphoma, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Dose-limiting toxicities at 28 days. Started Nov 2019; status: terminated.
02
Drugs
copanlisibvenetoclax
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03886649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886649.